The National Institute of Neurological Disorders and Stroke (NINDS) has awarded a five-year, $20 million grant to researchers looking for a way to image misfolded proteins in the brains of people with Parkinson’s and other neurodegenerative diseases, which could greatly advance diagnosis and disease monitoring. Parkinson’s disease is thought…
Cases of inherited Parkinson’s disease may be more frequent than previously reported, results from an online global survey suggest. The survey, which was conducted by members of The Michael J. Fox Foundation Global Genetic Parkinson’s Study Group (MJFF-GGPSG), also revealed the willingness of investigators to share clinical information on…
The Michael J. Fox Foundation (MJFF) and Massachusetts General Hospital have announced an initiative to enhance diversity in Parkinson’s disease research. Fostering Inclusivity in Research Engagement for Underrepresented Populations in Parkinson’s Disease (FIRE-UP PD) is an MJFF-funded study that will establish and assess outreach programs in Boston, Massachusetts, Weston,…
Yumanity Therapeutics announced the start of a Phase 1 clinical study in healthy volunteers that will assess the safety and tolerability of YTX-7739, a potential disease-modifying therapy for Parkinson’s disease. Trial results are expected to be announced in the first quarter of 2020. YTX-7739 is designed to cross the blood-brain-barrier…
MIT Lincoln Laboratory researchers are developing an artificial gut to study how the human microbiome — the trillions of microorganisms and their genetic material that live within our body, and are as unique to a person as fingerprints — influences the onset and progression of diseases linked to changes…
High intensity interval training for 12 weeks can significantly improve neuronal activity and delay progression of Parkinson’s disease, correlating with an improvement in patients’ quality of life, according to a recent study. The scientific poster, “High intensity interval training elevates circulating BDNF and miRNAs level in…
In calling for a public health campaign to promote a brain-healthy lifestyle, an Oxford Health Policy Forum report says people in middle age have a 10- to 20-year window of opportunity to potentially reduce the risk of developing neurodegenerative diseases such as Parkinson’s (PD), or to delay progression.
Parkinson’s disease (PD) is more common among males, but it tends to progress faster in females. This and other sex-based differences in the neurodegenerative disease were highlighted in a recent review, titled “Parkinson’s Disease in Women and Men: What’s the Difference?” and published in the…
Reduced viability and impaired activity of monocytes — a subset of immune cells that circulate in the blood — may contribute to the progression of Parkinson’s disease. That discovery, by researchers from Aarhus University in Denmark, may further understanding of the underlying mechanisms involved in the development and progression of…
Interim results from the ongoing Phase 3 HARMONY study show that treatment with Nuplazid (pimavanserin) significantly delays time to a psychosis relapse in patients with dementia-related disorders, such as Parkinson’s and Alzheimer’s disease. Evaluation by an independent data monitoring committee recommended an early stop to this placebo-controlled…
Get regular updates to your inbox.
